Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
暂无分享,去创建一个
[1] W. Hong,et al. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. , 2000, Cancer research.
[2] K. Bhalla,et al. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. , 2000, Blood.
[3] R. Lotan,et al. Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. , 2000, Molecular pharmacology.
[4] D. Baltimore,et al. Signal transduction: A cellular rescue team , 2000, Nature.
[5] E. Alnemri,et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. , 2000, Blood.
[6] J. Blenis,et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.
[7] D. Lawrence,et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. , 2000, Immunity.
[8] U. Reichert,et al. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases , 2000, Cell Death and Differentiation.
[9] P. Krammer,et al. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.
[10] J. Tschopp,et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.
[11] L. Altucci,et al. RAR‐independent RXR signaling induces t(15;17) leukemia cell maturation , 1999, The EMBO journal.
[12] P Chambon,et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. , 1999, Chemistry & biology.
[13] D. Lawrence,et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.
[14] J. Puck,et al. Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.
[15] V. Dixit,et al. Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.
[16] S. Minucci,et al. Retinoid receptors in health and disease: co-regulators and the chromatin connection. , 1999, Seminars in cell & developmental biology.
[17] W. Zong,et al. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis , 1999 .
[18] S. Gerondakis,et al. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. , 1999, Genes & development.
[19] J C Reed,et al. IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.
[20] C. Rauch,et al. Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.
[21] R. Gallagher,et al. The molecular biology of acute promyelocytic leukemia. , 1999, Cancer treatment and research.
[22] C. Y. Wang,et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.
[23] J. Tschopp,et al. Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.
[24] Marty W. Mayo,et al. NF-k B Antiapoptosis : Induction of TRAF 1 and TRAF 2 and c-IAP 1 and c-IAP 2 to Suppress Caspase-8 Activation , 1998 .
[25] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[26] M. You,et al. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein , 1997, Molecular and cellular biology.
[27] M. Sporn,et al. Recent advances in chemoprevention of cancer. , 1997, Science.
[28] C. Bloomfield,et al. All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.
[29] P. Fenaux,et al. Differentiation therapy for acute promyelocytic leukemia. , 1997, The New England journal of medicine.
[30] M. Malim,et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[31] M. Schweder,et al. Human A1, a Bcl-2-related gene, is induced in leukemic cells by cytokines as well as differentiating factors , 1997, Leukemia.
[32] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[33] Jacek Ostrowski,et al. Two distinct actions of retinoid-receptor ligands , 1996, Nature.
[34] R. Lotan. Retinoids in cancer chemoprevention , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] Philippe Kastner,et al. Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.
[36] G. Shipley,et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines , 1995, Molecular and cellular biology.
[37] M. Lanotte,et al. Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression. , 1995, Leukemia.
[38] M. Sporn,et al. The Retinoids : biology, chemistry, and medicine , 1994 .
[39] B. Barres,et al. Programmed cell death and the control of cell survival: lessons from the nervous system. , 1993, Science.
[40] S. Lippman,et al. 13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix , 1992 .
[41] R. Weber,et al. 13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin , 1992 .
[42] A. Székely,et al. Letter to the editor: Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid , 1991 .
[43] R Berger,et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). , 1991, Blood.
[44] A. Székely,et al. Topical treatment of epidemic Kaposi's sarcoma with all-trans-retinoic acid. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] P. Fenaux,et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. , 1990, Blood.
[46] A. Verma,et al. Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment. , 1987, Cancer research.
[47] M. Lilly,et al. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. , 1987, Blood.
[48] Najman,et al. NB 4 , a Maturation Inducible Cell Line With t ( 15 ; 17 ) Marker Isolated From a Human Acute Promyelocytic Leukemia ( M 3 ) , 2022 .